From willow bark to peptides: the ever widening spectrum of NF-kappaB inhibitors

Fulvio D'Acquisto; Angela Ianaro

doi:10.1016/j.coph.2006.02.009

From willow bark to peptides: the ever widening spectrum of NF-kappaB inhibitors

Research output: Contribution to journal › Review article › peer-review

Abstract

Inflammation disorders such as rheumatoid arthritis, asthma and inflammatory bowel disease can be considered as 'gene expression' diseases in which the pro-inflammatory gene program of the organism is aberrantly activated. Over the past 20 years, great attention has been given to the transcription factor nuclear factor-kappaB (NF-kappaB) for its involvement in inflammatory and immune diseases. Recently, several studies have been devoted to the development of new molecules that can prevent the expression of inflammatory genes by targeting NF-kappaB pathways. Therefore, it is possible to hypothesize that these molecules might represent the future class of drugs for the treatment of inflammatory diseases.

Original language	English
Pages (from-to)	387-92
Number of pages	6
Journal	Current opinion in pharmacology
Volume	6
Issue number	4
DOIs	https://doi.org/10.1016/j.coph.2006.02.009
Publication status	Published - Aug 2006

Keywords

Animals
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Aspirin
Glucocorticoids
Humans
Inflammation
NF-kappa B
Peptides
Plant Bark
Plant Extracts
Plant Preparations
Salicylates
Salix
Signal Transduction
Journal Article
Research Support, Non-U.S. Gov't
Review

Access to Document

10.1016/j.coph.2006.02.009

Cite this

@article{3573bf2391364e7ab77339833f69af3d,

title = "From willow bark to peptides: the ever widening spectrum of NF-kappaB inhibitors",

abstract = "Inflammation disorders such as rheumatoid arthritis, asthma and inflammatory bowel disease can be considered as 'gene expression' diseases in which the pro-inflammatory gene program of the organism is aberrantly activated. Over the past 20 years, great attention has been given to the transcription factor nuclear factor-kappaB (NF-kappaB) for its involvement in inflammatory and immune diseases. Recently, several studies have been devoted to the development of new molecules that can prevent the expression of inflammatory genes by targeting NF-kappaB pathways. Therefore, it is possible to hypothesize that these molecules might represent the future class of drugs for the treatment of inflammatory diseases.",

keywords = "Animals, Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Glucocorticoids, Humans, Inflammation, NF-kappa B, Peptides, Plant Bark, Plant Extracts, Plant Preparations, Salicylates, Salix, Signal Transduction, Journal Article, Research Support, Non-U.S. Gov't, Review",

author = "Fulvio D'Acquisto and Angela Ianaro",

year = "2006",

month = aug,

doi = "10.1016/j.coph.2006.02.009",

language = "English",

volume = "6",

pages = "387--92",

journal = "Current opinion in pharmacology",

issn = "1471-4892",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - From willow bark to peptides

T2 - the ever widening spectrum of NF-kappaB inhibitors

AU - D'Acquisto, Fulvio

AU - Ianaro, Angela

PY - 2006/8

Y1 - 2006/8

N2 - Inflammation disorders such as rheumatoid arthritis, asthma and inflammatory bowel disease can be considered as 'gene expression' diseases in which the pro-inflammatory gene program of the organism is aberrantly activated. Over the past 20 years, great attention has been given to the transcription factor nuclear factor-kappaB (NF-kappaB) for its involvement in inflammatory and immune diseases. Recently, several studies have been devoted to the development of new molecules that can prevent the expression of inflammatory genes by targeting NF-kappaB pathways. Therefore, it is possible to hypothesize that these molecules might represent the future class of drugs for the treatment of inflammatory diseases.

AB - Inflammation disorders such as rheumatoid arthritis, asthma and inflammatory bowel disease can be considered as 'gene expression' diseases in which the pro-inflammatory gene program of the organism is aberrantly activated. Over the past 20 years, great attention has been given to the transcription factor nuclear factor-kappaB (NF-kappaB) for its involvement in inflammatory and immune diseases. Recently, several studies have been devoted to the development of new molecules that can prevent the expression of inflammatory genes by targeting NF-kappaB pathways. Therefore, it is possible to hypothesize that these molecules might represent the future class of drugs for the treatment of inflammatory diseases.

KW - Animals

KW - Anti-Inflammatory Agents

KW - Anti-Inflammatory Agents, Non-Steroidal

KW - Aspirin

KW - Glucocorticoids

KW - Humans

KW - Inflammation

KW - NF-kappa B

KW - Peptides

KW - Plant Bark

KW - Plant Extracts

KW - Plant Preparations

KW - Salicylates

KW - Salix

KW - Signal Transduction

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

KW - Review

U2 - 10.1016/j.coph.2006.02.009

DO - 10.1016/j.coph.2006.02.009

M3 - Review article

C2 - 16781194

SN - 1471-4892

VL - 6

SP - 387

EP - 392

JO - Current opinion in pharmacology

JF - Current opinion in pharmacology

IS - 4

ER -